32 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA
6-K
EX-3.1
MREO
Mereo Biopharma Group Plc
18 Dec 23
Current report (foreign)
4:10pm
to give rise to a material conflict of interest; or
the Director’s conflict of interest arises from a permitted cause as set out in Article 19.4 … of interest or a conflict of interest arising in relation to a transaction or arrangement with the Company), the Directors may authorise in accordance
6-K
EX-3.1
MREO
Mereo Biopharma Group Plc
17 May 22
Current report (foreign)
8:26am
be regarded as likely to give rise to a material conflict of interest; or
the Director’s conflict of interest arises from a permitted cause as set out … to give rise to a conflict of interest or a conflict of interest arising in relation to a transaction or arrangement with the Company), the Directors may
6-K
EX-99.1
g7x05ez7u2xg9wq5
30 Apr 21
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
4:05pm
6-K
EX-10.1
tf9smzy
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
6-K
EX-10.2
5b41rbuit7i kg
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
dqito5w9kfk
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
kd0mxmld
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
F-1
k03fr08 j1jn
18 Feb 20
Registration statement (foreign)
5:15pm
20-F
EX-4.19
uu7uyzjb wi2
29 Apr 19
Annual report (foreign)
4:59pm
20-F
nxgl36dugqpm
29 Apr 19
Annual report (foreign)
4:59pm
424B3
qeclfdgqf6c3vdyqlrh
20 Mar 19
Prospectus supplement
4:58pm
F-4/A
oi9yct
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm